Featured content
Article
AACR 2026 part 1: AI design, precision biology and the next wave of oncology innovation
At AACR 2026, industry leaders discussed how oncology R&D is moving beyond isolated technological advances towards integrated discovery systems.
ArticleWomen in STEM: resilience and leadership in rare disease research
Rare neurological diseases remain one of the most challenging areas in drug discovery, with many patients still lacking treatment options. Dr Nitza Thomasson discusses returning to Servier to lead its rare neurology therapeutic area and explains why resilience, curiosity and persistence are essential for those looking to build a meaningful career in STEM.
ArticleDrug Target Review launches new website designed for drug discovery professionals
Drug Target Review has launched an updated website to improve access to content across early-stage drug discovery, alongside a new membership model that offers a gateway to premium analysis, reports and expert commentary.
ArticleWhen scale meets insight: reinventing SPR for the future of drug discovery
Carterra’s new 48-channel SPR platform reimagines throughput, automation and data quality for modern discovery workflows.
Opinion and interviews
Computational design drives new generation of synthetic promoters
Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Webinars
- Previous
- Next
Whitepapers
- Previous
- Next
